A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse-Reference-Cited by-同舟云学术

A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse

Published:2006-07 Issue:7 Volume:30 Page:777-783
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Moore Joseph,Seiter Karen,Kolitz Jonathan,Stock Wendy,Giles Francis,Kalaycio Matt,Zenk David,Marcucci Guido

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference24 articles.

1. How I treat older patients with AML;Estey;Blood,2000

2. Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse;Berger;Invest New Drugs,2002

3. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia;Bross;Clin Cancer Res,2001

4. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin);Larson;Leukemia,2002

5. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia;Karakas;Ann Oncol,1998

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress;Molecular Therapy - Nucleic Acids;2024-09

2. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

3. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice;Experimental Hematology & Oncology;2024-03-01

4. Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer;Cancers;2024-02-16

5. Mechanisms of Resistance to Antibody-Drug Conjugates;International Journal of Molecular Sciences;2023-06-02